Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19. (academic.oup.com)

Authors: Narayan K … Wingertzahn M Journal: Journal of Infectious Diseases Published: 2026-05-21 DOI: https://doi.org/10.1093/infdis/jiag269